Achieving Graft-Versus-Tumor Effect in Brain Tumor Patients: From Autologous Progenitor Cell Transplant to Active Immunotherapy

• Plosker GL , FiggittDP. Rituximab: a review of its use in non-Hodgkin‘s lymphoma and chronic lymphocytic leukaemia. Drugs63(8) , 803–843 (2003).
   PubMed Web of Science ®Google Scholar
• Yu AL , GilmanAL, OzkaynakMF et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363(14) , 1324–1334 (2010).
   PubMed Web of Science ®Google Scholar
• Gomez GG , KruseCA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther. Mol. Biol.10(A) , 133–146 (2006).
   PubMed Web of Science ®Google Scholar
• Yang I , HanSJ, KaurG, CraneC, ParsaAT. The role of microglia in central nervous system immunity and glioma immunology. J. Clin. Neurosci.17(1) , 6–10 (2010).
   PubMed Web of Science ®Google Scholar
• Graeber MB , ScheithauerBW, KreutzbergGW. Microglia in brain tumors. Glia40(2) , 252–259 (2002).
   PubMed Web of Science ®Google Scholar
• Chang CN , HuangYC, YangDM et al. A Phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J. Clin. Neurosci. 18(8) , 1048–1054 (2011).
   PubMed Web of Science ®Google Scholar
• Held-Feindt J , HattermannK, MüerkösterSS et al. CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs). Exp. Cell Res. 316(9) , 1553–1566 (2010).
   PubMed Web of Science ®Google Scholar
• Hussain SF , YangD, SukiD, AldapeK, GrimmE, HeimbergerAB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol.8(3) , 261–279 (2006).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI , ChenHL, GirgisKR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2(10) , 1096–1103 (1996).
   PubMed Web of Science ®Google Scholar
• Daga A , BottinoC, CastriconiR, GangemiR, FerriniS. New perspectives in glioma immunotherapy. Curr. Pharm. Des.17(23) , 2439–2467 (2011).
   PubMed Web of Science ®Google Scholar
• Dey M . The role of glioma microenvironment in immune modulation: potential targets for intervention. Lett. Drug Des. Discov.443–453 (2006).
   Web of Science ®Google Scholar
• Mehling M , SimonP, MittelbronnM et al. WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol. 114(2) , 111–119 (2007).
   PubMed Web of Science ®Google Scholar
• Zagzag D , SalnikowK, ChiribogaL et al. Downregulation of major histocompatibility complex antigens in invading glioma cells: stealth invasion of the brain. Lab. Invest. 85(3) , 328–341 (2005).
   PubMed Web of Science ®Google Scholar
• Castriconi R , DonderoA, NegriF et al. Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity. Eur. J. Immunol. 37(11) , 3190–3196 (2007).
   PubMed Web of Science ®Google Scholar
• Wu A , WiesnerS, XiaoJ et al. Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy. J. Neurooncol. 83(2) , 121–131 (2007).
   PubMed Web of Science ®Google Scholar
• Salsman VS , ChowKK, ShafferDR et al. Crosstalk between medulloblastoma cells and endothelium triggers a strong chemotactic signal recruiting T lymphocytes to the tumor microenvironment. PLoS One 6(5) , e20267 (2011).
   PubMed Web of Science ®Google Scholar
• Didenko VV , NgoHN, MinchewC, BaskinDS. Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J. Neurosurg.96(3) , 580–584 (2002).
   PubMed Web of Science ®Google Scholar
• Walker DG , ChuahT, RistMJ, PenderMP. T-cell apoptosis in human glioblastoma multiforme: implications for immunotherapy. J. Neuroimmunol.175(1–2) , 59–68 (2006).
   PubMed Web of Science ®Google Scholar
• Wei J , BarrJ, KongLY et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin. Cancer Res. 16(2) , 461–473 (2010).
   PubMed Web of Science ®Google Scholar
• Grauer OM , NierkensS, BenninkE et al. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int. J. Cancer 121(1) , 95–105 (2007).
   PubMed Web of Science ®Google Scholar
• Sonabend AM , RolleCE, LesniakMS. The role of regulatory T cells in malignant glioma. Anticancer Res.28(2B) , 1143–1150 (2008).
   PubMed Web of Science ®Google Scholar
• Charles NA , HollandEC, GilbertsonR, GlassR, KettenmannH. The brain tumor microenvironment. Glia59(8) , 1169–1180 (2011).
   PubMed Web of Science ®Google Scholar
• Masson F , CalzasciaT, Di Berardino-Besson W, de Tribolet N, Dietrich PY, Walker PR. Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J. Immunol.179(2) , 845–853 (2007).
   PubMed Web of Science ®Google Scholar
• Rasku MA , ClemAL, TelangS et al. Transient T cell depletion causes regression of melanoma metastases. J. Transl. Med. 6 , 12 (2008).
   PubMed Web of Science ®Google Scholar
• van der Most RG , CurrieAJ, RobinsonBW, LakeRA. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ.15(1) , 13–20 (2008).
   PubMed Web of Science ®Google Scholar
• Lake RA , RobinsonBW. Immunotherapy and chemotherapy – a practical partnership. Nat. Rev. Cancer5(5) , 397–405 (2005).
   PubMed Web of Science ®Google Scholar
• Haynes NM , van der Most RG, Lake RA, Smyth MJ. Immunogenic anti-cancer chemotherapy as an emerging concept. Curr. Opin. Immunol.20(5) , 545–557 (2008).
   PubMed Web of Science ®Google Scholar
• Baxevanis CN , PerezSA, PapamichailM. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol. Immunother.58(3) , 317–324 (2009).
   PubMed Web of Science ®Google Scholar
• van der Most RG , CurrieAJ, MahendranS et al. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol. Immunother. 58(8) , 1219–1228 (2009).
   PubMed Web of Science ®Google Scholar
• Banissi C , GhiringhelliF, ChenL, CarpentierAF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol. Immunother.58(10) , 1627–1634 (2009).
   PubMed Web of Science ®Google Scholar
• van der Most RG , CurrieA, RobinsonBW, LakeRA. Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res.66(2) , 601–604 (2006).
   PubMed Web of Science ®Google Scholar
• Marachelian A , ButturiniA, FinlayJ. Myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for childhood central nervous system tumors. Bone Marrow Transplant.41(2) , 167–172 (2008).
   PubMed Web of Science ®Google Scholar
• Foreman NK , SchisselD, LeT et al. A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors. J. Neurooncol. 71(2) , 181–187 (2005).
   PubMed Web of Science ®Google Scholar
• Gardner SL . Application of stem cell transplant for brain tumors. Pediatr. Transplant.8(Suppl. 5) , S28–S32 (2004).
   PubMed Web of Science ®Google Scholar
• Brandes AA , PalmisanoV, PasettoLM, BassoU, MonfardiniS. High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. Cancer Invest.19(1) , 41–48 (2001).
   PubMed Web of Science ®Google Scholar
• Massimino M , CohenKJ, FinlayJL. Is there a role for myeloablative chemotherapy with autologous hematopoietic cell rescue in the management of childhood high-grade astrocytomas? Pediatr. Blood Cancer54(4) , 641–643 (2010).
   PubMed Web of Science ®Google Scholar
• Finlay JL , DhallG, BoyettJM et al. Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children‘s Oncology Group. Pediatr. Blood Cancer 51(6) , 806–811 (2008).
   PubMed Web of Science ®Google Scholar
• Fagnoni FF , LozzaL, ZiberaC et al. Cytotoxic chemotherapy preceding apheresis of peripheral blood progenitor cells can affect the early reconstitution phase of naive T cells after autologous transplantation. Bone Marrow Transplant. 31(1) , 31–38 (2003).
   PubMed Web of Science ®Google Scholar
• Schrama JG , RodenhuisS, de Gast GC. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant.31(2) , 141–142 (2003).
   PubMed Web of Science ®Google Scholar
• Porrata LF , GertzMA, InwardsDJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 98(3) , 579–585 (2001).
   PubMed Web of Science ®Google Scholar
• Porrata LF , IngleJN, LitzowMR, GeyerS, MarkovicSN. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant.28(9) , 865–871 (2001).
   PubMed Web of Science ®Google Scholar
• Porrata LF , LitzowMR, TefferiA et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 16(7) , 1311–1318 (2002).
   PubMed Web of Science ®Google Scholar
• Agah R , MalloyB, KernerM, MazumderA. Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation. J. Immunol.143(9) , 3093–3099 (1989).
   PubMed Web of Science ®Google Scholar
• Agah R , MalloyB, KernerM et al. Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin 2-activated syngeneic bone marrow in mice. Cancer Res. 49(21) , 5959–5963 (1989).
   PubMed Web of Science ®Google Scholar
• Boyman O , SprentJ. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol.12(3) , 180–190 (2012).
   PubMed Web of Science ®Google Scholar
• Meehan KR , TalebianL, WuJ et al. Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected. Cytotherapy 12(8) , 1013–1021 (2010).
   PubMed Web of Science ®Google Scholar
• Sosman JA , StiffP, MossSM et al. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. J. Clin. Oncol. 19(3) , 634–644 (2001).
   PubMed Web of Science ®Google Scholar
• Nagler A , BergerR, AckersteinA et al. A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon α (IFN-α) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation. J. Immunother. 33(3) , 326–333 (2010).
   PubMed Web of Science ®Google Scholar
• Antony PA , RestifoNP. CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. J. Immunother.28(2) , 120–128 (2005).
   PubMed Web of Science ®Google Scholar
• Fehniger TA , CaligiuriMA. Interleukin 15: biology and relevance to human disease. Blood97(1) , 14–32 (2001).
   PubMed Web of Science ®Google Scholar
• Porrata LF , InwardsDJ, MicallefIN et al. Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas. Clin. Dev. Immunol. 2010 , 914945 (2010).
   PubMedGoogle Scholar
• Blaser BW , CaligiuriMA. Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15. Best Pract. Res. Clin. Haematol.19(2) , 281–292 (2006).
   PubMed Web of Science ®Google Scholar
• Hallett WH , MurphyWJ. Natural killer cells: biology and clinical use in cancer therapy. Cell. Mol. Immunol.1(1) , 12–21 (2004).
   PubMed Web of Science ®Google Scholar
• Aboody KS , NajbauerJ, DanksMK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther.15(10) , 739–752 (2008).
   PubMed Web of Science ®Google Scholar
• Sentman CL , BarberMA, BarberA, ZhangT. NK cell receptors as tools in cancer immunotherapy. Adv. Cancer Res.95 , 249–292 (2006).
   PubMed Web of Science ®Google Scholar
• Ishikawa E , TsuboiK, SaijoK et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res. 24(3b) , 1861–1871 (2004).
   PubMed Web of Science ®Google Scholar
• Vivier E , RauletDH, MorettaA et al. Innate or adaptive immunity? The example of natural killer cells. Science 331(6013) , 44–49 (2011).
   PubMed Web of Science ®Google Scholar
• Moretta L , FerlazzoG, BottinoC et al. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol. Rev. 214 , 219–228 (2006).
   PubMed Web of Science ®Google Scholar
• Andoniou CE , van Dommelen SL, Voigt V et al. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat. Immunol.6(10) , 1011–1019 (2005).
   PubMed Web of Science ®Google Scholar
• Voskens CJ , WatanabeR, RollinsS, CampanaD, HasumiK, MannDL. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J. Exp. Clin. Cancer Res.29 , 134 (2010).
   PubMed Web of Science ®Google Scholar
• Miller JS , SoignierY, Panoskaltsis-MortariA et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105(8) , 3051–3057 (2005).
   PubMed Web of Science ®Google Scholar
• Klingemann H , BoisselL. Targeted cellular therapy with natural killer cells. Horm. Metab. Res.40(2) , 122–125 (2008).
   PubMed Web of Science ®Google Scholar
• Müller T , UherekC, MakiG et al. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol. Immunother. 57(3) , 411–423 (2008).
   PubMed Web of Science ®Google Scholar
• Uherek C , TonnT, UherekB et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100(4) , 1265–1273 (2002).
   PubMed Web of Science ®Google Scholar
• Ahmed N , RatnayakeM, SavoldoB et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 67(12) , 5957–5964 (2007).
   PubMed Web of Science ®Google Scholar
• Lammering G , HewitTH, HolmesM et al. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin. Cancer Res. 10(19) , 6732–6743 (2004).
   PubMed Web of Science ®Google Scholar
• Farag SS , FehnigerTA, BecknellB, BlaserBW, CaligiuriMA. New directions in natural killer cell-based immunotherapy of human cancer. Expert Opin. Biol. Ther.3(2) , 237–250 (2003).
   PubMed Web of Science ®Google Scholar
• Ogbomo H , CinatlJ, ModyCH, ForsythPA. Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy. Trends Mol. Med.17(8) , 433–441 (2011).
   PubMed Web of Science ®Google Scholar
• Vauleon E , AvrilT, ColletB, MosserJ, QuillienV. Overview of cellular immunotherapy for patients with glioblastoma. Clin. Dev. Immunol.2010 (2010).
   Google Scholar
• Hayes RL , ArbitE, OdaimiM et al. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit. Rev. Oncol. Hematol. 39(1–2) , 31–42 (2001).
   PubMed Web of Science ®Google Scholar
• Finocchiaro G , PellegattaS. Immunotherapy for glioma: getting closer to the clinical arena? Curr. Opin. Neurol.24(6) , 641–647 (2011).
   PubMed Web of Science ®Google Scholar
• Dillman RO , DumaCM, EllisRA et al. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J. Immunother. 32(9) , 914–919 (2009).
   PubMed Web of Science ®Google Scholar
• Ehtesham M , BlackKL, YuJS. Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control11(3) , 192–207 (2004).
   PubMedGoogle Scholar
• Hofman FM , StathopoulosA, KruseCA, ChenTC, SchijnsVE. Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells. Anticancer Agents Med. Chem.10(6) , 462–470 (2010).
   PubMed Web of Science ®Google Scholar
• Tsuboi K , SaijoK, IshikawaE et al. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin. Cancer Res. 9(9) , 3294–3302 (2003).
   PubMed Web of Science ®Google Scholar
• Plautz GE , MillerDW, BarnettGH et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin. Cancer Res. 6(6) , 2209–2218 (2000).
   PubMed Web of Science ®Google Scholar
• Kronik N , KoganY, VainsteinV, AgurZ. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol. Immunother.57(3) , 425–439 (2008).
   PubMed Web of Science ®Google Scholar
• Chow KH , GottschalkS. Cellular immunotherapy for high-grade glioma. Immunotherapy3(3) , 423–434 (2011).
   PubMed Web of Science ®Google Scholar
• Ahmed N , SalsmanVS, KewY et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res. 16(2) , 474–485 (2010).
   PubMed Web of Science ®Google Scholar
• Kahlon KS , BrownC, CooperLJ, RaubitschekA, FormanSJ, JensenMC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res.64(24) , 9160–9166 (2004).
   PubMed Web of Science ®Google Scholar
• Bullain SS , SahinA, SzentirmaiO et al. Genetically engineered T cells to target EGFRvIII expressing glioblastoma. J. Neurooncol. 94(3) , 373–382 (2009).
   PubMed Web of Science ®Google Scholar
• Auletta JJ , CookeKR, SolchagaLA, DeansRJ, van‘t Hof W. Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions. Biol. Blood Marrow Transplant.16(7) , 891–906 (2010).
   PubMed Web of Science ®Google Scholar
• von Bahr L , SundbergB, LönniesL et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol. Blood Marrow Transplant. 18(4) , 557–564 (2012).
   PubMed Web of Science ®Google Scholar
• Nakamizo A , MariniF, AmanoT et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 65(8) , 3307–3318 (2005).
   PubMed Web of Science ®Google Scholar
• Hamada H , KobuneM, NakamuraK et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci. 96(3) , 149–156 (2005).
   PubMed Web of Science ®Google Scholar
• Aboody KS , BrownA, RainovNG et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl Acad. Sci. USA 97(23) , 12846–12851 (2000).
   PubMed Web of Science ®Google Scholar
• Binello E , GermanoIM. Stem cells as therapeutic vehicles for the treatment of high-grade gliomas. Neuro Oncol.14(3) , 256–265 (2012).
   PubMed Web of Science ®Google Scholar
• Roger M , ClavreulA, HuynhNT et al. Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal cells in brain tumor therapy. Int. J. Pharm. 423(1) , 63–68 (2012).
   PubMed Web of Science ®Google Scholar
• Kosztowski T , ZaidiHA, Quiñones-HinojosaA. Applications of neural and mesenchymal stem cells in the treatment of gliomas. Expert Rev. Anticancer Ther.9(5) , 597–612 (2009).
   PubMed Web of Science ®Google Scholar
• Casiraghi F , RemuzziG, AbbateM, PericoN. Multipotent mesenchymal stromal cell therapy and risk of malignancies. Stem Cell Rev. doi:10.1007/s12015-011-9345-4 (2012).
   Google Scholar
• Ciavarella S , DominiciM, DammaccoF, SilvestrisF. Mesenchymal stem cells: a new promise in anticancer therapy. Stem Cells Dev.20(1) , 1–10 (2011).
   PubMed Web of Science ®Google Scholar
• Kim W , LiauLM. Dendritic cell vaccines for brain tumors. Neurosurg. Clin. N. Am.21(1) , 139–157 (2010).
   PubMed Web of Science ®Google Scholar
• Akasaki Y , BlackKL, YuJS. Dendritic cell-based immunotherapy for malignant gliomas. Expert Rev. Neurother.5(4) , 497–508 (2005).
   PubMedGoogle Scholar
• Parajuli P , MathupalaS, MittalS, SloanAE. Dendritic cell-based active specific immunotherapy for malignant glioma. Expert Opin. Biol. Ther.7(4) , 439–448 (2007).
   PubMed Web of Science ®Google Scholar
• Ardon H , De Vleeschouwer S, Van Calenbergh F et al. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr. Blood Cancer54(4) , 519–525 (2010).
   PubMed Web of Science ®Google Scholar
• Ardon H , Van Gool S, Lopes IS et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J. Neurooncol.99(2) , 261–272 (2010).
   PubMed Web of Science ®Google Scholar
• Luptrawan A , LiuG, YuJS. Dendritic cell immunotherapy for malignant gliomas. Rev. Recent Clin. Trials3(1) , 10–21 (2008).
   PubMedGoogle Scholar
• Okada H , KalinskiP, UedaR et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 29(3) , 330–336 (2011).
   PubMed Web of Science ®Google Scholar
• Renga M , PedrazzoliP, SienaS. Present results and perspectives of allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of human solid tumors. Ann. Oncol.14(8) , 1177–1184 (2003).
   PubMed Web of Science ®Google Scholar
• Sung KW , ParkJE, ChuehHW et al. Reduced-intensity allogeneic stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation. Pediatr. Blood Cancer 57(4) , 660–665 (2011).
   PubMed Web of Science ®Google Scholar
• Hentschke P , BarkholtL, UzunelM et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant. 31(4) , 253–261 (2003).
   PubMed Web of Science ®Google Scholar
• Baird K , FryTJ, SteinbergSM et al. Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas. Biol. Blood Marrow Transplant. 18(5) , 698–707 (2012).
   PubMed Web of Science ®Google Scholar
• Secondino S , PedrazzoliP, SchiavettoI et al. Antitumor effect of allogeneic hematopoietic SCT in metastatic medulloblastoma. Bone Marrow Transplant. 42(2) , 131–133 (2008).
   PubMed Web of Science ®Google Scholar
• Lundberg JH , WeissmanDE, BeattyPA, AshRC. Treatment of recurrent metastatic medulloblastoma with intensive chemotherapy and allogeneic bone marrow transplantation. J. Neurooncol.13(2) , 151–155 (1992).
   PubMed Web of Science ®Google Scholar
• Leary SE , OlsonJM. The molecular classification of medulloblastoma: driving the next generation clinical trials. Curr. Opin. Pediatr.24(1) , 33–39 (2012).
   PubMed Web of Science ®Google Scholar
• Li Z , LeeJW, MukherjeeD et al. Immunotherapy targeting glioma stem cells – insights and perspectives. Expert Opin. Biol. Ther. 12(2) , 165–178 (2012).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Badie B. Phase I study of cellular immunotherapy for recurrent/refractory malignant glioma using intratumoral infusions of GRm13Z40-2, an allogeneic CD8+ cytolitic T-cell line genetically modified to express the IL 13-zetakine and HyTK and to be resistant to glucocorticoids, in combination with interleukin-2. http://www.clinicaltrials.gov/ct2/show/NCT01082926
   Google Scholar
• Portnow J. A pilot feasibility study of oral 5-fluorocytosine and genetically-modified neural stem cells expressing E. coli cytosine deaminase for treatment of recurrent high grade gliomas (2012). www.clinicaltrials.gov/ct2/show/NCT01172964
   Google Scholar
• Liau L. Study of a drug [DCVax®-L] to treat newly diagnosed GBM brain cancer (2012). www.clinicaltrials.gov/ct2/show/NCT00045968
   Google Scholar